Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For connected medical devices, how should sponsors approach cybersecurity documentation within a premarket submission to meet current FDA expectations? While specific requirements depend on the device...
As medical device manufacturers prepare for evolving WEEE and EPR regulations targeting 2026, selecting the right compliance partner is a critical strategic decision. Beyond simple registration, how c...
As international biocompatibility standards like the ISO 10993 series continue to evolve, how should medical device manufacturers proactively adapt their evaluation strategies to ensure ongoing compli...
When a foreign medical device establishment plans to market its products in the United States, designating a U.S. Agent is a mandatory regulatory requirement. But what are the core responsibilities of...
For a US-based manufacturer of a regulated medical device, such as a Class II pharmacogenetic assessment system defined under 21 CFR 862.3364, expanding into the European market involves navigating di...
As global Extended Producer Responsibility (EPR) and Waste from Electrical and Electronic Equipment (WEEE) regulations evolve towards key 2026 deadlines, how should a manufacturer of medical devices, ...
With the medical device landscape continuously evolving, particularly with anticipated updates to global biocompatibility standards, how should sponsors strategically evaluate and select a contract te...
With the UK MHRA establishing a deadline for non-UK medical device manufacturers to ensure their UK Responsible Person (UKRP) arrangements are updated, what are the critical operational and strategic ...
How does FDA approach the regulation of diagnostic software, and what are the key considerations for sponsors navigating this pathway? As software plays an increasingly critical role in healthcare, u...
With global WEEE and EPR regulations undergoing significant reforms, particularly with new producer definitions and stricter compliance requirements taking effect through 2026, how should a medical de...
As the medical device industry anticipates potential shifts in global biocompatibility standards around 2026, how can manufacturers move beyond baseline qualifications, such as general quality system ...
With key regulatory deadlines approaching for medical devices placed on the Great Britain market, how should a non-UK manufacturer strategically evaluate and select a UK Responsible Person (UKRP)? Bey...
With significant updates to regulations often having multi-year transition periods, what is a robust framework for cosmetic manufacturers to manage the evolving responsibilities of the EU Responsible ...
With significant global reforms to Waste Electrical and Electronic Equipment (WEEE) and Extended Producer Responsibility (EPR) frameworks expected through 2026, how can medical device manufacturers es...
With new global biocompatibility standards anticipated around 2026, medical device manufacturers face uncertainty in selecting long-term testing partners. Choosing a lab based solely on current accred...
With the UK's medical device regulatory framework evolving and key deadlines approaching, many non-UK manufacturers are re-evaluating their strategy for maintaining market access in Great Britain. The...
Given the significant updates to EU cosmetic regulations anticipated for 2026, how should a non-EU manufacturer conduct a comprehensive evaluation to select a Responsible Person (RP) that extends beyo...
For a non-EU company offering an AI-driven service, such as a health-tech application, that processes the personal data of EU residents, the upcoming EU AI Act introduces a new compliance layer alongs...
With significant updates to the ISO 10993 series of biocompatibility standards anticipated around 2025-2026, medical device manufacturers face uncertainty, particularly before global regulatory bodies...
When budgeting for a UK Responsible Person (UKRP) ahead of upcoming compliance deadlines, what specific factors and service-level components contribute to the overall cost, beyond a basic annual retai...